Department of Oncology, Helsinki University Central Hospital, Helsinki University, Haartmaninkatu 4, Helsinki FIN-00029, Finland.
Hematol Oncol Clin North Am. 2013 Oct;27(5):889-904. doi: 10.1016/j.hoc.2013.07.004. Epub 2013 Aug 2.
Adjuvant imatinib prolongs recurrence-free survival and probably overall survival of patients who have undergone surgery for gastrointestinal stromal tumor (GIST). Estimation of the risk of recurrence with a prognostication tool and tumor mutation analysis is essential before imatinib initiation, because approximately 60% of patients with GIST with operable tumor are cured by surgery alone and some mutated tyrosine kinases are insensitive to imatinib. Adjuvant imatinib is usually administered for 3 years at the dose of 400 mg once daily. Early detection of tumors that recur despite adjuvant therapy with longitudinal imaging of the abdomen is likely beneficial.
辅助伊马替尼可延长接受胃肠道间质瘤 (GIST) 手术治疗患者的无复发生存期和总生存期。在开始使用伊马替尼之前，使用预后工具和肿瘤突变分析来评估复发风险至关重要，因为大约 60% 的 GIST 患者可通过单独手术治愈，并且一些突变的酪氨酸激酶对伊马替尼不敏感。辅助伊马替尼通常以 400mg 每日一次的剂量使用 3 年。尽管采用辅助治疗，但通过腹部的纵向成像仍可能早期检测到复发的肿瘤，这可能有益。
